Tumor growth rate to assess therapy response to immune-based combinations for metastatic renal cell carcinoma

References

• Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. doi: 10.3322/caac.21763
   PubMed Web of Science ®Google Scholar
• Graves A, Hessamodini H, Wong G, et al. Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalities. Immunotargets Ther. 2013. 22(2):73–90. doi: 10.2147/ITT.S31426
   Google Scholar
• Navani V, Heng DYC. Treatment selection in first-line metastatic renal cell carcinoma—the contemporary treatment paradigm in the age of combination therapy: a review. JAMA Oncol. 2022;8(2):292–299.
   PubMed Web of Science ®Google Scholar
• Rosellini M, Marchetti A, Tassinari E, et al. Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer. Expert Rev Precis Med Drug Dev. 2022;7(1):131–149. doi: 10.1080/23808993.2022.2156786
   Web of Science ®Google Scholar
• Bolek H, Yekedüz E, Ürün Y. Combination therapies in patients with favorable risk metastatic renal cell carcinoma: a systematic review and meta-analysis. Cancer Treatment Reviews. 2024;122:102667. doi: 10.1016/j.ctrv.2023.102667
   PubMed Web of Science ®Google Scholar
• Brown JE, Royle KL, Gregory W, et al. Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial. Lancet Oncol. 2023;24(3):213–227. doi: 10.1016/S1470-2045(22)00793-8
   PubMed Web of Science ®Google Scholar
• Rosellini M, Marchetti A, Mollica V, et al. Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma. Nat Rev Urol. 2023;20(3):133–157. doi: 10.1038/s41585-022-00676-0
   PubMed Web of Science ®Google Scholar
• Boussios S, Devo P, Goodall ICA, et al. Exosomes in the diagnosis and treatment of renal cell cancer. Int J Mol Sci. 2023;24(18):14356.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non–small cell lung cancer treated with nivolumab. JAMA Oncol. 5(10):1411–1420. 2019 doi: 10.1001/jamaoncol.2019.2187
   PubMed Web of Science ®Google Scholar
• Dromain C, Beigelman C, Pozzessere C, et al. Imaging of tumour response to immunotherapy. Eur Radiol Exp. 2020;4(1):2. doi: 10.1186/s41747-019-0134-1
   PubMedGoogle Scholar
• Queirolo P, Spagnolo F. Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: a systematic review. Cancer Treat Rev. 2017;59:71–78. doi: 10.1016/j.ctrv.2017.07.002
   PubMed Web of Science ®Google Scholar
• Hwang I, Park I, Yoon SK, et al. Hyperprogressive disease in patients with urothelial carcinoma or renal cell carcinoma treated with PD-1/PD-L1 inhibitors. Clin Genitourin Cancer. 2020;18(2):e122–e133. doi: 10.1016/j.clgc.2019.09.009
   PubMed Web of Science ®Google Scholar
• Luo J, Wu S, Rizvi H, et al. Deciphering radiological stable disease to immune checkpoint inhibitors. Ann Oncol. 2022;33(8):824–835. doi: 10.1016/j.annonc.2022.04.450
   PubMed Web of Science ®Google Scholar
• Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143–e152. doi: 10.1016/S1470-2045(17)30074-8
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412–7420. doi: 10.1158/1078-0432.CCR-09-1624
   PubMed Web of Science ®Google Scholar
• Grande E, Martínez-Sáez O, Gajate-Borau P, et al. Translating new data to the daily practice in second line treatment of renal cell carcinoma: the role of tumor growth rate. World J Clin Oncol. 2017. 8(2):100–105. doi: 10.5306/wjco.v8.i2.100
   PubMed Web of Science ®Google Scholar
• Gomez-Roca C, Koscielny S, Ribrag V, et al. Tumour growth rates and RECIST criteria in early drug development. Eur J Cancer. 2011;47(17):2512–2516. doi: 10.1016/j.ejca.2011.06.012
   PubMed Web of Science ®Google Scholar
• Lamarca A, Ronot M, Moalla S, et al. Tumor growth rate as a validated early radiological biomarker able to reflect treatment-induced changes in neuroendocrine tumors: the GREPONET-2 study. Clin Cancer Res. 2019;25(22):6692–6699. doi: 10.1158/1078-0432.CCR-19-0963
   PubMed Web of Science ®Google Scholar
• He LN, Fu S, Ma H, et al. Early on-treatment tumor growth rate (EOT-TGR) determines treatment outcomes of advanced non-small-cell lung cancer patients treated with programmed cell death protein 1 axis inhibitor. ESMO Open. 2022;7(6):100630. doi: 10.1016/j.esmoop.2022.100630
   PubMed Web of Science ®Google Scholar
• Ramtohul T, Cohen A, Rodrigues M, et al. Tumour growth rate improves tumour assessment and first-line systemic treatment decision-making for immunotherapy in patients with liver metastatic uveal melanoma. Br J Cancer. 2022;127(2):258–267. doi: 10.1038/s41416-022-01793-8
   PubMed Web of Science ®Google Scholar
• Dall’olio FG, Parisi C, Marcolin L, et al. Monitoring tumor growth rate to predict immune checkpoint inhibitors’ treatment outcome in advanced NSCLC. Ther Adv Med Oncol. 2022;14:17588359211058391. doi: 10.1177/17588359211058391
   Google Scholar
• Ferté C, Koscielny S, Albiges L, et al. Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data. Eur Urol. 2014;65(4):713–720. doi: 10.1016/j.eururo.2013.08.010
   PubMed Web of Science ®Google Scholar
• Stein WD, Wilkerson J, Kim ST, et al. Analyzing the pivotal trial that compared sunitinib and IFN-α in renal cell carcinoma, using a method that assesses tumor regression and growth. Clin Cancer Res. 2012;18(8):2374–2381. doi: 10.1158/1078-0432.CCR-11-2275
   PubMed Web of Science ®Google Scholar
• Iacovelli R, Massari F, Albiges L, et al. Evidence and clinical relevance of Tumor flare in patients who discontinue tyrosine kinase inhibitors for treatment of metastatic renal cell carcinoma. Eur Urol. 2015;68(1):154–160. doi: 10.1016/j.eururo.2014.10.034
   PubMed Web of Science ®Google Scholar
• Mollica V, Brocchi S, Dall’olio FG, et al. Tumor growth rate decline despite progressive disease may predict improved nivolumab treatment outcome in mRCC: when RECIST is not enough. Cancers (Basel). 2021;13(14):3492. doi: 10.3390/cancers13143492
   PubMed Web of Science ®Google Scholar
• Quhal F, Mori K, Remzi M, et al. Adverse events of systemic immune-based combination therapies in the first-line treatment of patients with metastatic renal cell carcinoma: systematic review and network meta-analysis. Curr Opin Urol. 2021;31(4):332–339. doi:10.1097/MOU.0000000000000889
   PubMed Web of Science ®Google Scholar
• Ivanyi P, Wiegmann JP, Eggers H, et al. First line medical treatment of metastatic renal cell carcinoma: a podcast on choosing wisely and managing safely. Adv Ther. 2023;40(9):3620–3625. doi: 10.1007/s12325-023-02571-5
   PubMed Web of Science ®Google Scholar
• Savaliya M, Surati D, Surati R, et al. Posterior reversible encephalopathy syndrome after pazopanib therapy. Diseases. 2023;11(2):76. doi: 10.3390/diseases11020076
   PubMedGoogle Scholar
• Rosellini M, Mollica V, Marchetti A, et al. Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis. Pathol Res Pract. 2024;254:155142. doi: 10.1016/j.prp.2024.155142
   PubMed Web of Science ®Google Scholar
• Saliby RM, Saad E, Kashima S, Schoenfeld DABraun DA Update on Biomarkers in Renal Cell Carcinoma. Am Soc Clin Oncol Educ Book. 2024;44(2):e430734. doi: 10.1200/EDBK_430734
   PubMedGoogle Scholar
• Navani V, Ernst M, Wells JC, et al. Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma. JAMA Netw Open. 2022;5(6):e2216379.
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47. doi: 10.3390/ijms241814356
   PubMed Web of Science ®Google Scholar